Vertex Pharmaceuticals Incorporated: Revision history

28 July 2023

• curprev 10:2310:23, 28 July 2023‎ 85.255.234.252 talk‎ 24,119 bytes +35‎ No edit summary undo Tag: Visual edit

27 July 2023

• curprev 17:4117:41, 27 July 2023‎ 2.101.82.82 talk‎ 24,084 bytes +549‎ No edit summary undo Tag: Visual edit
• curprev 16:1316:13, 27 July 2023‎ Dan Ritchie talk contribs‎ 23,535 bytes +3,407‎ No edit summary undo Tag: Visual edit

26 July 2023

• curprev 15:4815:48, 26 July 2023‎ 2.101.82.82 talk‎ 20,128 bytes +18‎ No edit summary undo Tag: Visual edit
• curprev 15:3915:39, 26 July 2023‎ 2.101.82.82 talk‎ 20,110 bytes +9,487‎ No edit summary undo Tag: Visual edit
• curprev 13:0313:03, 26 July 2023‎ Dan Ritchie talk contribs‎ 10,623 bytes +3,189‎ added key people bios undo Tag: Visual edit
• curprev 11:2811:28, 26 July 2023‎ Call 23 talk contribs‎ 7,434 bytes +3,815‎ No edit summary undo Tag: Visual edit

22 July 2023

• curprev 13:5513:55, 22 July 2023‎ Manos talk contribs‎ 3,619 bytes −1,639‎ No edit summary undo Tag: Visual edit
• curprev 13:5413:54, 22 July 2023‎ Manos talk contribs‎ 5,258 bytes +3,592‎ No edit summary undo Tag: Visual edit: Switched

18 July 2023

• curprev 12:1012:10, 18 July 2023‎ Lasen talk contribs‎ 1,666 bytes +4‎ No edit summary undo Tag: Visual edit

21 August 2022

• curprev 00:1800:18, 21 August 2022‎ 95.149.241.133 talk‎ 1,662 bytes +11‎ No edit summary undo Tag: Visual edit: Switched

14 August 2022

• curprev 12:5012:50, 14 August 2022‎ 109.180.50.163 talk‎ 1,651 bytes +15‎ No edit summary undo Tag: Visual edit: Switched

8 August 2022

• curprev 02:4602:46, 8 August 2022‎ Paris talk contribs‎ 1,636 bytes +1,636‎ Created page with "Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes V..." Tag: Visual edit